Asia Pacific Randomization And Trial Supply Management Rtsm Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2023 –2030 |
 Market Size (Base Year) |
USD 362.08 Million |
 Market Size (Forecast Year) |
USD 1,084.71 Million |
 CAGR |
% |
| Major Markets Players |
亚太随机化和试验供应管理 (RTSM) 市场，按组件（软件、服务）、交付模式（许可企业（本地）、基于云的 (SaaS)、基于 Web 的（按需）、应用程序（情景规划和预测、聚合/批次规划、研究构建、随机化、药物分配、重新预测和优化、销毁和协调、数据库锁定、库存管理、其他）、临床试验类型（治疗试验、预防试验、筛查试验、支持性护理试验）、临床试验阶段（早期、I 期临床试验、II 期临床试验、III 期临床试验、IV 期临床试验和围/后批准）、治疗领域（肿瘤学、心血管疾病和循环系统疾病、传染病、消化系统疾病、肌肉骨骼疾病、神经系统疾病、内分泌和代谢疾病、精神健康和行为障碍、血液病、呼吸系统疾病等）、最终用户（制药和生物制药公司、合同研究组织、医疗器械制造商、医院、学术研究机构、政府机构等）、分销渠道（直销、第三方分销商）——行业趋势和预测到 2030 年。
亚太地区随机化和试验供应管理 (RTSM) 市场分析和规模
根据 ISR 2020 IRT 报告，申办方和 CRO 希望临床试验的 RTSM 易于集成，能够快速启动研究，并以合理的成本提供满足其特定复杂程度试验所需的功能。拥有丰富试验需求经验的临床试验 RTSM 合作伙伴至关重要，尤其是考虑到当今的试验涉及的患者、地点、国家和不确定性比以往任何时候都多。影响随机化和供应链试验管理的问题的数量和复杂性也在增加，目前正在考虑昂贵的对照药物、复杂的方案、精细的试验化合物、适应性临床试验和可变的给药方案。
Data Bridge Market Research 分析，随机化和试验供应管理 (RTSM) 市场在 2022 年为 3.6208 亿美元，到 2030 年将飙升至 10.8471 亿美元，预计在 2023 年至 2030 年的预测期内复合年增长率为 14.7%。除了市场价值、增长率、细分市场、地理覆盖范围、市场参与者和市场情景等市场洞察外，Data Bridge Market Research 团队策划的市场报告还包括深入的专家分析、患者流行病学、管道分析、定价分析和监管框架。
亚太地区随机化和试验供应管理 (RTSM) 市场范围和细分
|
报告指标 |
细节 |
|
预测期 |
2023 至 2030 年 |
|
基准年 |
2022 |
|
历史岁月 |
2021 (Customizable to 2015 - 2020) |
|
Quantitative Units |
Revenue in USD Million, Volumes in Units, Pricing in USD |
|
Segments Covered |
Component (Software, Services), Delivery Mode (Licensed Enterprise (On-Premise), Cloud-Based (SaaS), Web Based (On-Demand), Application (Scenario Planning and Forecasting, Aggregation/ Lot Planning, Study Build, Randomization, Drug Dispensing, Reforecast and Optimize, Destruction and Reconciliation, Database Lock, Inventory Management, Others), Clinical Trial Type (Treatment Trials, Prevention Trials, Screening Trials, Supportive Care Trials), Clinical Trial Phase (Early Phase, Phase I clinical trials, Phase II clinical trials, Phase III clinical trials, Phase IV clinical trials and Peri-/Post- Approval), Therapeutic Area (Oncology, Cardiovascular Disease and Circulatory Diseases, Infectious Diseases, Digestive Diseases, Musculoskeletal Diseases, Nervous System Diseases, Endocrinology and Metabolic Diseases, Mental Health and Behavioural Disorders, Blood Diseases, Respiratory Diseases, Others), End User (Pharmaceutical and Biopharmaceutical Companies, Contract Research Organizations, Medical Device Manufacturers, Hospitals, Academic Research Institutes, Government Bodies, Others), Distribution Channel ( Direct Sales, Third Party Distributor) |
|
Countries Covered |
China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC) |
|
Market Players Covered |
MEDICAL Information Technology Inc. (U.S.), SAP (Germany), CPSI (U.S.), Meta (U.S.), Elinext (U.S.), EPIC Systems Corporation (U.S.), INFOR (U.S.), Cognizant (U.S.), Oracle (U.S.), Jag products LLC (U.S.), Allscripts Healthcare LLC (U.S.), Optum Inc. (U.S.), Cerner Corporation (U.S.), Change Healthcare (U.S.), Koninklijke Philips N.V. (Netherlands), athenahealth (U.S.), eClinicalWorks (U.S.) |
|
Market Opportunities |
|
Market Definition
Randomization and trial supply management (RTSM) is a management system that allows critical clinical trial functions such as randomizing patients to determine who receives drugs and placebo treatments, drug dispensing capacity to ensure the correct dose of drugs to trial patients, and controlling the flow of drug from pharmaceutical or biotechnology companies to the clinical site. RTSM is in charge of patient tracking, medication administration, cohort management, site activation, and keeping the entire clinical study confidential. The primary goal of RTSM is to prevent any bias in deciding which patients are assigned to which treatment group during each phase of a clinical trial, as well as to ensure, track, manage, and safely distribute products to patients from manufacturers.
Randomization and Trial Supply Management (RTSM) Market Dynamics
Drivers
- Increased adoption of new software solutions
Rising government funding for clinical trials, the introduction of e-clinical solutions to improve data standardisation, and rising pharmaceutical company expenditure for drug development pipeline allocation are some of the factors that will likely accelerate the growth of the randomization and trial supply management (RTSM) market between 2023 and 2030.
- Increasing number of clinical trials
The increasing number of clinical trials in developing economies and the outsourcing of clinical trial operations by many sectors would provide numerous opportunities for the randomization and trial supply management (RTSM) market. For instance, according to clinical trials data, as of July 25, 2022, 10,548 clinical trials for cancer, 6,349 for cardiology, and 947 for neurology, among other studies, were registered. As a result, the growth is expected to be aided by the large number of clinical trials registered under phase III.
Opportunities
Increasing awareness among the patients concerning the prevailing advantages of management solutions will help in boosting lucrative opportunities in the growth of the market.
Restraints/Challenges
- Lack of skilled professionals
High cost of implementation and lack of skilled professionals which will hamper the growth of the randomization and trial supply management (RTSM) market in the above mentioned forecast period.
This randomization and trial supply management (RTSM) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the randomization and trial supply management (RTSM) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In April 2019, IBM Corporation launched Advanced Storage Solutions Designed to Simplify Data Accessibility and Availability Across Hybrid Clouds. This new solution launched by parent company IBM has increased the company's overall revenue for market.
- In February 2021, ICON plc announced that it had reached a definitive agreement to acquire PRA Health Sciences, Inc. The goal of this strategic acquisition was for both companies to improve clinical trial management in order to provide more value to patients, customers, employees, and shareholders.
Asia-Pacific Randomization and Trial Supply Management (RTSM) Market Scope
随机化和试验供应管理 (RTSM) 市场根据组件、交付模式、应用、临床试验类型、临床试验阶段、治疗领域、最终用户和分销渠道进行细分。这些细分市场之间的增长将帮助您分析行业中增长微弱的细分市场，并为用户提供有价值的市场概览和市场洞察，帮助他们做出战略决策，确定核心市场应用。
成分
- 软件
- 服务
交付方式
- 授权企业（本地）
- 基于云的（SaaS）
- 基于 Web（按需）
应用
- 情景规划和预测
- 集合/批次规划
- 研究构建、随机化
- 药品调配
- 重新预测和优化
- 毁灭与和解
- 数据库锁
- 库存管理
- 其他的
临床试验类型
- 治疗试验
- 预防试验
- 筛选试验
- 支持治疗试验
临床试验阶段
- 早期阶段
- I期临床试验
- II期临床试验
- III期临床试验
- IV期临床试验
- 审批前后
治疗领域
- 肿瘤学
- 心血管疾病和循环系统疾病
- 传染病
- 消化系统疾病
- 肌肉骨骼疾病
- 神经系统疾病
- 内分泌与代谢疾病
- 心理健康和行为障碍
- 血液疾病
- 呼吸系统疾病
- 其他的
最终用户
- 制药和生物制药公司
- 合同研究组织
- 医疗器械制造商
- 医院、学术研究机构
- 政府机构
- 其他的
分销渠道
- 直销
- 第三方分销商
随机化和试验供应管理 (RTSM) 市场区域分析/见解
对随机化和试验供应管理 (RTSM) 市场进行了分析，并按国家、组成部分、交付模式、应用、临床试验类型、临床试验阶段、治疗领域、最终用户和分销渠道提供了市场规模洞察和趋势。
随机化和试验供应管理 (RTSM) 市场报告涵盖的国家包括亚太地区的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区 (APAC) 其他地区。
凭借医疗保健领域的发展，日本有望在亚太地区 (APAC) 占据主导地位。
报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。
竞争格局和随机化及试验供应管理 (RTSM) 市场份额分析
随机化和试用供应管理 (RTSM) 市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对随机化和试用供应管理 (RTSM) 市场的关注有关。
随机化和试验供应管理 (RTSM) 市场的一些主要参与者包括：
- 医疗信息技术公司（美国）
- SAP（德国）
- CPSI（美国）
- Meta（美国）
- Elinext（美国）
- EPIC Systems Corporation（美国）
- INFOR（美国）
- Cognizant（美国）
- 甲骨文 (美国)
- Jag products LLC（美国）
- Allscripts Healthcare LLC（美国）
- Optum Inc.（美国）
- Cerner Corporation（美国）
- 改变医疗保健（美国）
- Koninklijke Philips NV（荷兰）
- athenahealth（美国）
- eClinicalWorks（美国）
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
